Ignite Creation Date:
2025-12-24 @ 4:01 PM
Ignite Modification Date:
2025-12-26 @ 7:19 AM
Study NCT ID:
NCT00436566
Status:
COMPLETED
Last Update Posted:
2022-08-05
First Post:
2007-02-15
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery
Sponsor:
Mayo Clinic
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
CDR0000533793
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | NIH | View |